In vitro phosphorylation does not influence the aggregation kinetics of WT α-synuclein in contrast to its phosphorylation mutants

International Journal of Molecular Sciences

Volumn 15, Issue 1, 2014, Pages 1040-1067

  Schreurs, Sarah ^a   Gerard, Melanie ^a   Derua, Rita ^b   Waelkens, Etienne ^b   Taymans, Jean Marc ^a   Baekelandt, Veerle ^a   Engelborghs, Yves ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b LABORATORY OF MOLECULAR AND CELLULAR SIGNALING   (Belgium)

Author keywords

Alpha synuclein; FKBP; In vitro fibrillization; Parkinson's disease; Phosphorylation; Phosphorylation mutants

Indexed keywords

ALPHA-SYNUCLEIN; HUMANS; KINETICS; MUTATION, MISSENSE; PHOSPHORYLATION; POLYMERIZATION; TACROLIMUS BINDING PROTEINS;

EID: 84892623172     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms15011040     Document Type: Article

References (61)

1. Spillantini, M.G.; Schmidt, M.L.; Lee, V.M.; Trojanowski, J.Q.; Jakes, R.; Goedert, M. Alpha-synuclein in Lewy bodies. Nature 1997, 388, 839-840.
2. Baba, M.; Nakajo, S.; Tu, P.H.; Tomita, T.; Nakaya, K.; Lee, V.M.; Trojanowski, J.Q.; Iwatsubo, T. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 1998, 152, 879-884.
3. Bertoncini, C.W.; Jung, Y.S.; Fernandez, C.O.; Hoyer, W.; Griesinger, C.; Jovin, T.M.; Zweckstetter, M. Release of long-range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein. Proc. Natl. Acad. Sci. USA 2005, 102, 1430-1435.
4. Dedmon, M.M.; Lindorff-Larsen, K.; Christodoulou, J.; Vendruscolo, M.; Dobson, C.M. Mapping long-range interactions in alpha-synuclein using spin-label NMR and ensemble molecular dynamics simulations. J. Am. Chem. Soc. 2005, 127, 476-477.
5. Abeliovich, A.; Schmitz, Y.; Farinas, I.; Choi-Lundberg, D.; Ho, W.H.; Castillo, P.E.; Shinsky, N.; Verdugo, J.M.; Armanini, M.; Ryan, A.; et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 2000, 25, 239-252.
6. Lundblad, M.; Decressac, M.; Mattsson, B.; Bjorklund, A. Impaired neurotransmission caused by overexpression of alpha-synuclein in nigral dopamine neurons. Proc. Natl. Acad. Sci. USA 2012, 109, 3213-3219.
7. Cooper, A.A.; Gitler, A.D.; Cashikar, A.; Haynes, C.M.; Hill, K.J.; Bhullar, B.; Liu, K.; Xu, K.; Strathearn, K.E.; Liu, F.; et al. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 2006, 313, 324-328.
8. Nemani, V.M.; Lu, W.; Berge, V.; Nakamura, K.; Onoa, B.; Lee, M.K.; Chaudhry, F.A.; Nicoll, R.A.; Edwards, R.H. Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 2010, 65, 66-79.
9. Kahle, P.J.; Neumann, M.; Ozmen, L.; Haass, C. Physiology and pathophysiology of alpha-synuclein: Cell culture and transgenic animal models based on a Parkinson's disease-associated protein. Ann. N. Y. Acad. Sci. 2000, 920, 33-41.
10. Scott, D.A.; Tabarean, I.; Tang, Y.; Cartier, A.; Masliah, E.; Roy, S. A pathologic cascade leading to synaptic dysfunction in alpha-synuclein-induced neurodegeneration. J. Neurosci. 2010, 30, 8083-8095.
11. Scott, D.; Roy, S. Alpha-synuclein inhibits intersynaptic vesicle mobility and maintains recycling-pool homeostasis. J. Neurosci. 2012, 32, 10129-10135.
12. Anderson, J.P.; Walker, D.E.; Goldstein, J.M.; de Laat, R.; Banducci, K.; Caccavello, R.J.; Barbour, R.; Huang, J.; Kling, K.; Lee, M.; et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 2006, 281, 29739-29752.
13. Fujiwara, H.; Hasegawa, M.; Dohmae, N.; Kawashima, A.; Masliah, E.; Goldberg, M.S.; Shen, J.; Takio, K.; Iwatsubo, T. Alpha-synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 2002, 4, 160-164.
14. Hirai, Y.; Fujita, S.C.; Iwatsubo, T.; Hasegawa, M. Phosphorylated alpha-synuclein in normal mouse brain. FEBS Lett. 2004, 572, 227-232.
15. Paleologou, K.E.; Schmid, A.W.; Rospigliosi, C.C.; Kim, H.-Y.; Lamberto, G.R.; Fredenburg, R.A.; Lansbury, P.T.; Fernandez, C.O.; Eliezer, D.; Zweckstetter, M.; et al. Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein. J. Biol. Chem. 2008, 283, 16895-16905.
16. Chen, L.; Feany, M.B. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat. Neurosci. 2005, 8, 657-663.
17. Chau, K.Y.; Ching, H.L.; Schapira, A.H.; Cooper, J.M. Relationship between alpha synuclein phosphorylation, proteasomal inhibition and cell death: Relevance to Parkinson's disease pathogenesis. J. Neurochem. 2009, 110, 1005-1013.
18. Azeredo da Silveira, S.; Schneider, B.L.; Cifuentes-Diaz, C.; Sage, D.; Abbas-Terki, T.; Iwatsubo, T.; Unser, M.L.; Aebischer, P. Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease. Hum. Mol. Genet. 2009, 18, 872-887.
19. Gorbatyuk, O.S.; Li, S.; Sullivan, L.F.; Chen, W.; Kondrikova, G.; Manfredsson, F.P.; Mandel, R.J.; Muzyczka, N. The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease. Proc. Natl. Acad. Sci. USA 2008, 105, 763-768.
20. McFarland, N.R.; Fan, Z.; Xu, K.; Schwarzschild, M.A.; Feany, M.B.; Hyman, B.T.; McLean, P.J. Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease. J. Neuropathol. Exp. Neurol. 2009, 68, 515-524.
21. Okochi, M.; Walter, J.; Koyama, A.; Nakajo, S.; Baba, M.; Iwatsubo, T.; Meijer, L.; Kahle, P.J.; Haass, C. Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. J. Biol. Chem. 2000, 275, 390-397.
22. Waxman, E.A.; Giasson, B.I. Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein. J. Neuropathol. Exp. Neurol. 2008, 67, 402-416.
23. Arawaka, S.; Wada, M.; Goto, S.; Karube, H.; Sakamoto, M.; Ren, C.-H.; Koyama, S.; Nagasawa, H.; Kimura, H.; Kawanami, T.; et al. The role of G-protein-coupled receptor kinase 5 in pathogenesis of sporadic Parkinson's disease. J. Neurosci. Off. J. Soc. Neurosci. 2006, 26, 9227-9238.
24. Pronin, A.N.; Morris, A.J.; Surguchov, A.; Benovic, J.L. Synucleins are a novel class of substrates for G protein-coupled receptor kinases. J. Biol. Chem. 2000, 275, 26515-26522.
25. Inglis, K.J.; Chereau, D.; Brigham, E.F.; Chiou, S.S.; Schobel, S.; Frigon, N.L.; Yu, M.; Caccavello, R.J.; Nelson, S.; Motter, R.; et al. Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system. J. Biol. Chem. 2009, 284, 2598-2602.
26. Mbefo, M.K.; Paleologou, K.E.; Boucharaba, A.; Oueslati, A.; Schell, H.; Fournier, M.; Olschewski, D.; Yin, G.; Zweckstetter, M.; Masliah, E.; et al. Phosphorylation of synucleins by members of the Polo-like kinase family. J. Biol. Chem. 2010, 285, 2807-2822.
27. Negro, A.; Brunati, A.M.; Donella-Deana, A.; Massimino, M.L.; Pinna, L.A. Multiple phosphorylation of alpha-synuclein by protein tyrosine kinase Syk prevents eosin-induced aggregation. J. Off. Publ. Feder. Am. Soc. Exp. Biol. 2002, 16, 210-212.
28. Ellis, C.E.; Schwartzberg, P.L.; Grider, T.L.; Fink, D.W.; Nussbaum, R.L. Alpha-synuclein is phosphorylated by members of the Src family of protein-tyrosine kinases. J. Biol. Chem. 2001, 276, 3879-3884.
29. Nakamura, T.; Yamashita, H.; Takahashi, T.; Nakamura, S. Activated Fyn phosphorylates alpha-synuclein at tyrosine residue 125. Biochem. Biophys. Res. Commun. 2001, 280, 1085-1092.
30. Ahn, B.H.; Rhim, H.; Kim, S.Y.; Sung, Y.M.; Lee, M.Y.; Choi, J.Y.; Wolozin, B.; Chang, J.S.; Lee, Y.H.; Kwon, T.K.; et al. Alpha-Synuclein interacts with phospholipase D isozymes and inhibits pervanadate-induced phospholipase D activation in human embryonic kidney-293 cells. J. Biol. Chem. 2002, 277, 12334-12342.
31. Chen, L.; Periquet, M.; Wang, X.; Negro, A.; McLean, P.J.; Hyman, B.T.; Feany, M.B. Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. J. Clin. Investig. 2009, 119, 3257-3265.
32. Deleersnijder, A.; van Rompuy, A.S.; Desender, L.; Pottel, H.; Buee, L.; Debyser, Z.; Baekelandt, V.; Gerard, M. Comparative analysis of different peptidyl-prolyl isomerases reveals FK506-binding protein 12 as the most potent enhancer of alpha-synuclein aggregation. J. Biol. Chem. 2011, 286, 26687-26701.
33. Gerard, M.; Debyser, Z.; Desender, L.; Baert, J.; Brandt, I.; Baekelandt, V.; Engelborghs, Y. FK506 binding protein 12 differentially accelerates fibril formation of wild type alpha-synuclein and its clinical mutants A30P or A53T. J. Neurochem. 2008, 106, 121-133.
34. Gerard, M.; Deleersnijder, A.; Daniels, V.; Schreurs, S.; Munck, S.; Reumers, V.; Pottel, H.; Engelborghs, Y.; van den Haute, C.; Taymans, J.M.; et al. Inhibition of FK506 binding proteins reduces alpha-synuclein aggregation and Parkinson's disease-like pathology. J. Neurosci. 2010, 30, 2454-2463.
35. Hong, D.P.; Fink, A.L.; Uversky, V.N. Structural characteristics of alpha-synuclein oligomers stabilized by the flavonoid baicalein. J. Mol. Biol. 2008, 383, 214-223.
36. Nath, S.; Meuvis, J.; Hendrix, J.; Carl, S.A.; Engelborghs, Y. Early aggregation steps in alpha-synuclein as measured by FCS and FRET: Evidence for a contagious conformational change. Biophys. J. 2010, 98, 1302-1311.
37. Morar, A.S.; Olteanu, A.; Young, G.B.; Pielak, G.J. Solvent-induced collapse of alpha-synuclein and acid-denatured cytochrome c. Protein Sci. 2001, 10, 2195-2199.
38. Paleologou, K.E.; Oueslati, A.; Shakked, G.; Rospigliosi, C.C.; Kim, H.Y.; Lamberto, G.R.; Fernandez, C.O.; Schmid, A.; Chegini, F.; Gai, W.P.; et al. Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions. J. Neurosci. 2010, 30, 3184-3198.
39. Gerard, M.; Debyser, Z.; Desender, L.; Kahle, P.J.; Baert, J.; Baekelandt, V.; Engelborghs, Y. The aggregation of alpha-synuclein is stimulated by FK506 binding proteins as shown by fluorescence correlation spectroscopy. FASEB J. 2006, 20, 524-526.
40. Meuvis, J.; Gerard, M.; Desender, L.; Baekelandt, V.; Engelborghs, Y. The conformation and the aggregation kinetics of alpha-synuclein depend on the proline residues in its C-terminal region. Biochemistry 2010, 49, 9345-9352.
41. Kuwahara, T.; Tonegawa, R.; Ito, G.; Mitani, S.; Iwatsubo, T. Phosphorylation of alpha-synuclein protein at Ser-129 reduces neuronal dysfunction by lowering its membrane binding property in Caenorhabditis elegans. J. Biol. Chem. 2012, 287, 7098-7109.
42. Visanji, N.P.; Wislet-Gendebien, S.; Oschipok, L.W.; Zhang, G.; Aubert, I.; Fraser, P.E.; Tandon, A. Effect of Ser-129 phosphorylation on interaction of alpha-synuclein with synaptic and cellular membranes. J. Biol. Chem. 2011, 286, 35863-35873.
43. Hashimoto, M.; Hsu, L.J.; Sisk, A.; Xia, Y.; Takeda, A.; Sundsmo, M.; Masliah, E. Human recombinant NACP/alpha-synuclein is aggregated and fibrillated in vitro: Relevance for Lewy body disease. Brain Res. 1998, 799, 301-306.
44. Uversky, V.N.; Oldfield, C.J.; Dunker, A.K. Showing your ID: Intrinsic disorder as an ID for recognition, regulation and cell signaling. J. Mol. Recognit. 2005, 18, 343-384.
45. Yamin, G.; Uversky, V.N.; Fink, A.L. Nitration inhibits fibrillation of human alpha-synuclein in vitro by formation of soluble oligomers. FEBS Lett. 2003, 542, 147-152.
46. Lu, Y.; Prudent, M.; Fauvet, B.; Lashuel, H.A.; Girault, H.H. Phosphorylation of alpha-synuclein at Y125 and S129 alters its metal binding properties: Implications for understanding the role of alpha-synuclein in the pathogenesis of Parkinson's disease and related disorders. ACS Chem. Neurosci. 2011, 2, 667-675.
47. Hejjaoui, M.; Butterfield, S.; Fauvet, B.; Vercruysse, F.; Cui, J.; Dikiy, I.; Prudent, M.; Olschewski, D.; Zhang, Y.; Eliezer, D.; et al. Elucidating the role of C-terminal post-translational modifications using protein semisynthesis strategies: Alpha-synuclein phosphorylation at tyrosine 125. J. Am. Chem. Soc. 2012, 134, 5196-5210.
48. Ulrih, N.P.; Barry, C.H.; Fink, A.L. Impact of Tyr to Ala mutations on alpha-synuclein fibrillation and structural properties. Biochim. Biophys. Acta 2008, 1782, 581-585.
49. Gothel, S.F.; Marahiel, M.A. Peptidyl-prolyl cis-trans isomerases, a superfamily of ubiquitous folding catalysts. Cell. Mol. Life Sci. 1999, 55, 423-436.
50. Edlich, F.; Weiwad, M.; Wildemann, D.; Jarczowski, F.; Kilka, S.; Moutty, M.C.; Jahreis, G.; Lucke, C.; Schmidt, W.; Striggow, F.; et al. The specific FKBP38 inhibitor N-(N', N'-dimethylcarboxamidomethyl)cycloheximide has potent neuroprotective and neurotrophic properties in brain ischemia. J. Biol. Chem. 2006, 281, 14961-14970.
51. Gold, B.G.; Udina, E.; Bourdette, D.; Navarro, X. Neuroregenerative and neuroprotective actions of neuroimmunophilin compounds in traumatic and inflammatory neuropathies. Neurol. Res. 2004, 26, 371-380.
52. Gold, B.G.; Zeleny-Pooley, M.; Wang, M.S.; Chaturvedi, P.; Armistead, D.M. A nonimmunosuppressant FKBP-12 ligand increases nerve regeneration. Exp. Neurol 1997, 147, 269-278.
53. Van Raaij, M.E.; Segers-Nolten, I.M.; Subramaniam, V. Quantitative morphological analysis reveals ultrastructural diversity of amyloid fibrils from alpha-synuclein mutants. Biophys. J. 2006, 91, L96-L98.
54. Kumar, A.; Greggio, E.; Beilina, A.; Kaganovich, A.; Chan, D.; Taymans, J.M.; Wolozin, B.; Cookson, M.R. The Parkinson's disease associated LRRK2 exhibits weaker in vitro phosphorylation of 4E-BP compared to autophosphorylation. PLoS One 2010, 5, e8730.
55. Schapira, A.H. Etiology of Parkinson's disease. Neurology 2006, 66, S10-S23.
56. Takahashi, M.; Ko, L.W.; Kulathingal, J.; Jiang, P.; Sevlever, D.; Yen, S.H. Oxidative stress-induced phosphorylation, degradation and aggregation of alpha-synuclein are linked to upregulated CK2 and cathepsin D. Eur. J. Neurosci. 2007, 26, 863-874.
57. Vancraenenbroeck, R.; Lobbestael, E.; de Maeyer, M.; Baekelandt, V.; Taymans, J.M. Kinases as targets for Parkinson's disease: from genetics to therapy. CNS Neurol. Disord. Drug Targets 2011, 10, 724-740.
58. Kostka, M.; T. Hogen, K.M.; Danzer, J.; Levin, M.; Habeck, A.; Wirth, R.; Wagner, C.G.; Glabe, S.; Finger, U.; Heinzelmann, P.; et al. Single particle characterization of iron-induced pore-forming alpha-synuclein oligomers. J. Biol. Chem. 2008, 283, 10992-11003.
59. Petrásek, Z.; Schwille, P. Precise measurement of diffusion coefficients using scanning fluorescence correlation spectroscopy. Biophys. J. 2008, 94, 1437-1448.
60. Kullertz, G.; Luthe, S.; Fischer, G. Semiautomated microtiter plate assay for monitoring peptidylprolyl cis/trans isomerase activity in normal and pathological human sera. Clin. Chem. 1998, 44, 502-508.
61. Olsen, J.V.; Vermeulen, M.; Santamaria, A.; Kumar, C.; Miller, M.L.; Jensen, L.J.; Gnad, F.; Cox, J.; Jensen, T.S.; Nigg, E.A.; et al. Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci. Signal 2010, doi:10.1126/scisignal.2000475.